Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 4th edition, 372 pages + the daily Top 10

Lung Cancer

Free Subscription 18.05.2020 1 Am J Respir Crit Care Med 1 Am J Surg 1 Ann Surg Oncol 1 Ann Thorac Surg 1 Anticancer Res 3 Arch Bronconeumol 1 Arch Pathol Lab Med 1 BMC Cancer 1 Br J Cancer 1 Cancer 2 Cancer Sci 2 Chest 6 Clin Lung Cancer 1 Eur J Cancer 1 Int J Radiat Oncol Biol Phys 1 J Cancer Res Clin Oncol 1 J Clin Oncol 3 J Thorac Cardiovasc Surg 2 J Thorac Oncol 2 JAMA Oncol 2 Lancet Oncol 7 Lung Cancer 4 N Engl J Med 1 Oncogene 1 Oncologist 1 PLoS Comput Biol 2 PLoS One 1 Proc Natl Acad Sci U S A 1 Thorax

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Respir Crit Care Med

1. CHRISTIANI DC
   Occupational Exposures and Lung Cancer.
   Am J Respir Crit Care Med. 2020 May 12. doi: 10.1164/rccm.202004-1404.
   PubMed        
   
   

   
   Am J Surg

2. SINGH B, Singh G, Alzahrani N, Morris DL, et al
   Long term survival and perioperative propensity score matched outcomes of diaphragmatic resections compared to stripping in cytoreductive surgery + intra-peritoneal chemotherapy.
   Am J Surg. 2020;219:673-680.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

3. EBY ME, Seder CW
   The Landmark Series: Multimodality Therapy for Stage 3A Non-small Cell Lung Cancer.
   Ann Surg Oncol. 2020 May 9. pii: 10.1245/s10434-020-08553.
   PubMed        
   
   

   
   Ann Thorac Surg

4. REULING EMBP, Daniels JMA, Dickhoff C
   Sublobar Resection of Typical Carcinoid Tumors of the Lung.
   Ann Thorac Surg. 2020;109:989-990.
   PubMed        
   
   

   
   Anticancer Res

5. SHIBATA MA, Shibata E, Morimoto J, Kondo Y, et al
   Urethane-induced Mammary Carcinogenesis Susceptibility in Transgenic Mice Expressing a Dominant-negative TGF-beta Type II Receptor.
   Anticancer Res. 2020;40:2687-2694.
   PubMed         Abstract available
   
   

   
   Arch Bronconeumol

6. TRAVIER N, Fu M, Romaguera A, Martin-Cantera C, et al
   6-Year Risk of Developing Lung Cancer in Spain: Analysis by Autonomous Communities.
   Arch Bronconeumol. 2020 May 10. pii: S0300-2896(20)30103.
   PubMed         Abstract available
   
   
7. DE LA VINA JI, Mayol J, Ortega AL, Navarrete BA, et al
   [Lung cancer patients on the waiting list in the midst of the COVID-19 crisis: What do we do now?]
   Arch Bronconeumol. 2020 May 13. pii: S0300-2896(20)30142.
   PubMed        
   
   
8. DE-TORRES JP, Wisnivesky JP, Bastarrika G, Wilson DO, et al
   Exploring the Impact of Lung Cancer Screening on Lung Cancer Mortality of Smokers With Obstructive Lung Disease: Analysis of the NLST-ACRIN Cohort.
   Arch Bronconeumol. 2020 May 12. pii: S0300-2896(20)30104.
   PubMed         Abstract available
   
   

   
   Arch Pathol Lab Med

9. DERAKHSHAN F, Ionescu D, Cheung S, Churg A, et al
   Use of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions.
   Arch Pathol Lab Med. 2020;144:185-188.
   PubMed         Abstract available
   
   

   
   BMC Cancer

10. BERKOVIC P, Gulyban A, Defraene G, Swenen L, et al
    Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases.
    BMC Cancer. 2020;20:402.
    PubMed         Abstract available
    
    

    
    Br J Cancer

11. WELCH CA, Sweeting MJ, Lambert PC, Rutherford MJ, et al
    Impact on survival of modelling increased surgical resection rates in patients with non-small-cell lung cancer and cardiovascular comorbidities: a VICORI study.
    Br J Cancer. 2020 May 11. pii: 10.1038/s41416-020-0869.
    PubMed         Abstract available
    
    

    
    Cancer

12. MARSHALL CH, Al-Mallah MH, Dardari Z, Brawner CA, et al
    Cardiorespiratory fitness and incident lung and colorectal cancer in men and women: Results from the Henry Ford Exercise Testing (FIT) cohort.
    Cancer. 2019 May 6. doi: 10.1002/cncr.32085.
    PubMed         Abstract available
    
    

    
    Cancer Sci

13. FUKUDA K, Takeuchi S, Arai S, Kita K, et al
    GSK-3 inhibition overcomes EMT-associated resistance to osimertinib in EGFR mutant lung cancer.
    Cancer Sci. 2020 May 11. doi: 10.1111/cas.14454.
    PubMed         Abstract available
    
    
14. AKAZAWA Y, Saito Y, Yoshikawa T, Saito K, et al
    Efficacy of immunotherapy targeting the neoantigen derived from EGFR T790M/C797S mutation in non-small cell lung cancer.
    Cancer Sci. 2020 May 11. doi: 10.1111/cas.14451.
    PubMed         Abstract available
    
    

    
    Chest

15. WIENER RS, Clark JA, Koppelman E, Bolton R, et al
    Patient versus Clinician Perspectives on Communication about Results of Lung Cancer Screening: A Qualitative Study.
    Chest. 2020 May 6. pii: S0012-3692(20)30860-6. doi: 10.1016/j.chest.2020.
    PubMed         Abstract available
    
    
16. RAY MA, Faris NR, Derrick A, Smeltzer MP, et al
    Rurality, Stage-Stratified Use of Treatment Modalities and Survival of Non-small Cell Lung Cancer.
    Chest. 2020 May 6. pii: S0012-3692(20)30868-0. doi: 10.1016/j.chest.2020.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

17. DE GIGLIO A, Lamberti G, Facchinetti F, Genova C, et al
    Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
    Clin Lung Cancer. 2020 Apr 15. pii: S1525-7304(20)30087.
    PubMed         Abstract available
    
    
18. STINCHCOMBE TE, Miksad RA, Gossai A, Griffith SD, et al
    Real-World Outcomes for Advanced Non-Small Cell Lung Cancer Patients Treated With a PD-L1 Inhibitor Beyond Progression.
    Clin Lung Cancer. 2020 Apr 18. pii: S1525-7304(20)30107.
    PubMed         Abstract available
    
    
19. GELATTI ACZ, Cordeiro de Lima VC, Freitas H, Werutsky G, et al
    Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Apr 13. pii: S1525-7304(20)30106.
    PubMed         Abstract available
    
    
20. CHIAPPETTA M, Leuzzi G, Sperduti I, Bria E, et al
    Mediastinal Up-Staging During Surgery in Non-Small-Cell Lung Cancer: Which Mediastinal Lymph Node Metastasis Patterns Better Predict The Outcome? A Multicenter Analysis.
    Clin Lung Cancer. 2020 Mar 20. pii: S1525-7304(20)30082.
    PubMed         Abstract available
    
    
21. ABDEL-RAHMAN O
    Incidence and Mortality of Lung Cancer Among Never Smokers in Relationship to Secondhand Smoking: Findings From the PLCO Trial.
    Clin Lung Cancer. 2020 Apr 13. pii: S1525-7304(20)30108.
    PubMed         Abstract available
    
    
22. MUKTHINUTHALAPATI VVPK, Putta A, Farooq MZ, Singh SRK, et al
    Knowledge, Attitudes, and Practices Pertaining to Lung Cancer Screening Among Primary Care Physicians in a Public Urban Health Network.
    Clin Lung Cancer. 2020 Apr 11. pii: S1525-7304(20)30083.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

23. FACCHINETTI F, Lacroix L, Mezquita L, Scoazec JY, et al
    Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF(V600E) non-small cell lung cancer.
    Eur J Cancer. 2020;132:211-223.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

24. ZENG Y, Liu Q, Wang Y, Tian C, et al
    CDK5 activates Hippo signaling to confer resistance to radiotherapy via upregulating TAZ in lung cancer.
    Int J Radiat Oncol Biol Phys. 2020 May 11. pii: S0360-3016(20)31129.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

25. MU Y, Hao X, Xing P, Hu X, et al
    Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
    J Cancer Res Clin Oncol. 2020 May 8. pii: 10.1007/s00432-020-03239.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

26. KENMOTSU H, Yamamoto N, Yamanaka T, Yoshiya K, et al
    Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2020 May 14:JCO1902674. doi: 10.1200/JCO.19.02674.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

27. XIE D, Deng J, Gonzalez-Rivas D, Zhu Y, et al
    Comparison of video-assisted thoracoscopic surgery with thoracotomy in bronchial sleeve lobectomy for centrally located non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2020 Mar 25. pii: S0022-5223(20)30719.
    PubMed         Abstract available
    
    
28. JEFFREY YANG CF
    Commentary: Is surgery better than chemoradiation for T3N1M0 non-small cell lung cancer?
    J Thorac Cardiovasc Surg. 2020 Apr 6. pii: S0022-5223(20)30805.
    PubMed        
    
    
29. OPITZ I
    Commentary: Surgery expanding to stage IV non-small cell lung cancer treatment?!
    J Thorac Cardiovasc Surg. 2020 Mar 31. pii: S0022-5223(20)30731.
    PubMed        
    
    

    
    J Thorac Oncol

30. ZHU J, Zhang Y, Gao XH, Xi EP, et al
    COVID-19 or Lung Cancer: A differential diagnostic experience and management model from Wuhan.
    J Thorac Oncol. 2020 May 6. pii: S1556-0864(20)30377.
    PubMed        
    
    
31. HONG L, Negrao MV, Dibaj SS, Chen R, et al
    Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2020 May 7. pii: S1556-0864(20)30373.
    PubMed         Abstract available
    
    

    
    JAMA Oncol

32. MIYAMOTO S, Azuma K, Ishii H, Bessho A, et al
    Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.
    JAMA Oncol. 2020 May 14:e201250. doi: 10.1001/jamaoncol.2020.1250.
    PubMed         Abstract available
    
    
33. LIU Y, Colditz GA, Kozower BD, James A, et al
    Association of Medicaid Expansion Under the Patient Protection and Affordable Care Act With Non-Small Cell Lung Cancer Survival.
    JAMA Oncol. 2020 May 14. pii: 2765753. doi: 10.1001/jamaoncol.2020.1040.
    PubMed        
    
    

    
    Lancet Oncol

34. SHU CA, Gainor JF, Awad MM, Chiuzan C, et al
    Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
    Lancet Oncol. 2020 May 7. pii: S1470-2045(20)30140.
    PubMed         Abstract available
    
    
35. ROSELL R, Ito M
    Neoadjuvant atezolizumab plus chemotherapy in resectable non-small-cell lung cancer.
    Lancet Oncol. 2020 May 7. pii: S1470-2045(20)30146.
    PubMed        
    
    

    
    Lung Cancer

36. TAKADA K, Takamori S, Yoneshima Y, Tanaka K, et al
    Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy.
    Lung Cancer. 2020;145:18-26.
    PubMed         Abstract available
    
    
37. LIN YT, Tsai TH, Wu SG, Liu YN, et al
    Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer.
    Lung Cancer. 2020;145:1-9.
    PubMed         Abstract available
    
    
38. POPAT S, Grohe C, Corral J, Reck M, et al
    Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?
    Lung Cancer. 2020;144:76-84.
    PubMed         Abstract available
    
    
39. DENG J, Zhao M, Wang T, She Y, et al
    A modified T categorization for part-solid lesions in Chinese patients with clinical stage I Non-small cell lung cancer.
    Lung Cancer. 2020;145:33-39.
    PubMed         Abstract available
    
    
40. CHEN V, Iwama E, Kim IK, Giaccone G, et al
    Serum CRIPTO does not confer drug resistance against osimertinib but is an indicator of tumor burden in non-small cell lung cancer.
    Lung Cancer. 2020;145:48-57.
    PubMed         Abstract available
    
    
41. HOFMAN V, Benzaquen J, Heeke S, Lassalle S, et al
    Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry: A single laboratory experience (LPCE, Nice, France).
    Lung Cancer. 2020;145:58-62.
    PubMed         Abstract available
    
    
42. SERENO M, Gutierrez-Gutierrez G, Sandoval C, Falagan S, et al
    A favorable outcome of pneumonia COVID 19 in an advanced lung cancer patient with severe neutropenia: Is immunosuppression a risk factor for SARS-COV2 infection?
    Lung Cancer. 2020 May 4. pii: S0169-5002(20)30399.
    PubMed        
    
    

    
    N Engl J Med

43. RAMALINGAM SS, Soria JC
    Osimertinib in EGFR-Mutated Advanced NSCLC. Reply.
    N Engl J Med. 2020;382:1864-1865.
    PubMed        
    
    
44. REVANNASIDDAIAH S, Devadas SK, Maka VV
    Osimertinib in EGFR-Mutated Advanced NSCLC.
    N Engl J Med. 2020;382:1864.
    PubMed        
    
    
45. STAEGE MS
    Osimertinib in EGFR-Mutated Advanced NSCLC.
    N Engl J Med. 2020;382:1863-1864.
    PubMed        
    
    
46. YAN K
    Osimertinib in EGFR-Mutated Advanced NSCLC.
    N Engl J Med. 2020;382:1863.
    PubMed        
    
    

    
    Oncogene

47. KWON OS, Lee H, Kong HJ, Kwon EJ, et al
    Connectivity map-based drug repositioning of bortezomib to reverse the metastatic effect of GALNT14 in lung cancer.
    Oncogene. 2020 May 9. pii: 10.1038/s41388-020-1316.
    PubMed         Abstract available
    
    

    
    Oncologist

48. TAKAYAMA K, Takeshita M, Inoue K, Ichiki M, et al
    Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non-Small Cell Lung Cancer: LOGIK0801.
    Oncologist. 2020 May 9. doi: 10.1634/theoncologist.2020-0322.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

49. RICHARD M, Decamps C, Chuffart F, Brambilla E, et al
    PenDA, a rank-based method for personalized differential analysis: Application to lung cancer.
    PLoS Comput Biol. 2020;16:e1007869.
    PubMed         Abstract available
    
    

    
    PLoS One

50. JUSTO N, Nilsson J, Korytowsky B, Dalen J, et al
    Retrospective observational cohort study on innovation in oncology and progress in survival: How far have we gotten in the two decades of treating patients with advanced non-small cell lung cancer as a single population?
    PLoS One. 2020;15:e0232669.
    PubMed         Abstract available
    
    
51. LU Y, Liu X, Zhang E, Kopras EJ, et al
    Estrogen activates pyruvate kinase M2 and increases the growth of TSC2-deficient cells.
    PLoS One. 2020;15:e0228894.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

52. WINKLER I, Bitter C, Winkler S, Weichenhan D, et al
    Identification of Ppargamma-modulated miRNA hubs that target the fibrotic tumor microenvironment.
    Proc Natl Acad Sci U S A. 2020;117:454-463.
    PubMed         Abstract available
    
    

    
    Thorax

53. CRAWLEY D, Breen RA, Elkington PT, Karapanagiotou E, et al
    Tuberculosis associated with Triplet therapy for lung cancer.
    Thorax. 2020 May 14. pii: thoraxjnl-2019-213913.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: